Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

374 ARTÍCULOS , VIENDO DEL 211 AL 225

Solanezumab: too late in mild Alzheimer's disease?

The Lancet Neurology.

Lancet Neurol. 2017 Feb;16(2):97. doi: 10.1016/S1474-4422(16)30395-7.

Acute renal failure caused by cilostazol in a patient with Alzheimer's disease

Nomoto H, Matsubara Y, Ichimiya Y, Arai H.

Geriatr Gerontol Int. 2017 Jan;17(1):171-172. doi: 10.1111/ggi.12760.

Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial

Decourt B, Drumm-Gurnee D, Wilson J, Jacobson S, Belden C, Sirrel S, Ahmadi M, Shill H, Powell J, Walker A, Gonzales A, Macias M, Sabbagh MN.

Curr Alzheimer Res. 2017;14(4):403-411. doi: 10.2174/1567205014666170117141330.

Targeting β-amyloid plaques and oligomers: development of near-IR fluorescence imaging probes

Liu H, Yang J, Wang L, Xu Y, Zhang S, Lv J, Ran C, Li Y.

Future Med Chem. 2017 Feb;9(2):179-198. doi: 10.4155/fmc-2016-0185. Epub 2017 Jan 27.

Pharmacological Therapy for Apathy in Alzheimer's Disease: A Systematic Review and Meta-Analysis

Sepehry AA, Sarai M, Hsiung GR.

Can J Neurol Sci. 2017 May;44(3):267-275. doi: 10.1017/cjn.2016.426. Epub 2017 Feb 2.

Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial

Jia J, Wei C, Jia L, Tang Y, Liang J, Zhou A, Li F, Shi L, Doody RS.

J Alzheimers Dis. 2017;56(4):1495-1504. doi: 10.3233/JAD-161117.

Nanotechnology for Alzheimer Disease

Leszek J, Md Ashraf G, Tse WH, Zhang J, Gasiorowski K, Avila-Rodriguez MF, Tarasov VV, Barreto GE, Klochkov SG, Bachurin SO, Aliev G.

Curr Alzheimer Res. 2017;14(11):1182-1189. doi: 10.2174/1567205014666170203125008.

Galantamine Response Associates with Agitation and the Prefrontal Cortex in Patients with Alzheimer's Disease

Nakayama S, Suda A, Nakanishi A, Motoi Y, Hattori N.

J Alzheimers Dis. 2017;57(1):267-273. doi: 10.3233/JAD-160902.

Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalities

Theleritis C, Siarkos K, Katirtzoglou E, Politis A.

J Geriatr Psychiatry Neurol. 2017 Jan;30(1):26-49. doi: 10.1177/0891988716678684.

Low Florbetapir PET Uptake and Normal Aβ1-42 Cerebrospinal Fluid in an APP Ala713Thr Mutation Carrier

Lombardi G, Berti V, Tedde A, Bagnoli S, Piaceri I, Polito C, Lucidi G, Ferrari C, Ginestroni A, Moretti M, Pupi A, Nacmias B, Sorbi S.

J Alzheimers Dis. 2017;57(3):697-703. doi: 10.3233/JAD-161170.

Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease

Reeves S, McLachlan E, Bertrand J, D'Antonio F, Brownings S, Nair A, Greaves S, Smith A, Taylor D, Dunn J, Marsden P, Kessler R, Howard R.

Brain. 2017 Apr 1;140(4):1117-1127. doi: 10.1093/brain/aww359.

Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials

Fleisher AS, Joshi AD, Sundell KL, Chen YF, Kollack-Walker S, Lu M, Chen S, Devous MD Sr, Seibyl J, Marek K, Siemers ER, Mintun MA.

Alzheimers Dement. 2017 Oct;13(10):1117-1124. doi: 10.1016/j.jalz.2017.02.009. Epub 2017 Mar 30.

Alzheimer Disease: Monotherapy vs. Combination Therapy

Lawler E, Avila A.

Am Fam Physician. 2017 Apr 1;95(7):452.

Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial

Xiao S, Wang T, Ma X, Qin Y, Li X, Zhao Z, Liu X, Wang X, Xie H, Jiang Q, Sun L, Luo B, Shang L, Chen W, Bai Y, Tang M, He M, Wu L, Ma Q, Hou D, He J.

Age Ageing. 2017 Sep 1;46(5):767-773. doi: 10.1093/ageing/afx045.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias